The University of Southampton
University of Southampton Institutional Repository

MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation

MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation
MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation
BACKGROUND: Irreversible airflow obstruction in Chronic Obstructive Pulmonary Disease (COPD) is thought to result from airway remodelling associated with aberrant inflammation. Patients who experience frequent episodes of acute deterioration in symptoms and lung function, termed exacerbations, experience a faster decline in their lung function, and thus over time greater disease severity. However the mechanisms by which these episodes may contribute to decreased lung function are poorly understood. This study has prospectively examined changes in sputum levels of inflammatory cells, MMP-9 and TIMP-1 during exacerbations comparing with paired samples taken prior to exacerbation. METHODS: Nineteen COPD patients ((median, [IQR]) age 69 [63 to 74], forced expiratory volume in one second (FEV1) 1.0 [0.9 to 1.2], FEV1% predicted 37.6 [27.3 to 46.2]) provided sputa at exacerbation. Of these, 12 were paired with a samples collected when the patient was stable, a median 4 months [2 to 8 months] beforehand. RESULTS: MMP-9 levels increased from 10.5 microg/g [1.2 to 21.1] prior to exacerbation to 17.1 microg/g [9.3 to 48.7] during exacerbation (P < 0.01). TIMP-1 levels decreased from 3.5 microg/g [0.6 to 7.8] to 1.5 microg/g [0.3 to 4.9] (P = 0.16). MMP-9/TIMP-1 Molar ratio significantly increased from 0.6 [0.2 to 1.1] to 3.6 [2.0 to 25.3] (P < 0.05). Neutrophil, eosinophil and lymphocyte counts all showed significant increase during exacerbation compared to before (P < 0.05). Macrophage numbers remained level. MMP-9 levels during exacerbation showed highly significant correlation with both neutrophil and lymphocyte counts (Rho = 0.7, P < 0.01). CONCLUSION: During exacerbation, increased inflammatory burden coincides with an imbalance of the proteinase MMP-9 and its cognate inhibitor TIMP-1. This may suggest a pathway connecting frequent exacerbations with lung function decline.
1465-9921
151-[9pp]
Mercer, P.F.
6859877c-f46f-4f00-a0a8-56859973d842
Shute, J.K.
21aa47b2-7a14-4706-981d-f6cc6be58bf4
Bhowmik, A.
f7bc595d-eb75-48ab-b4d7-98a4fb47a258
Donaldson, G.C.
918ca6d7-df9d-4c9b-add7-8de7f9f5ab70
Wedizicha, J.A.
8d5f0942-8d89-4e9e-8718-6fe39a936543
Warner, J.A.
8571b049-31bb-4a2a-a3c7-4184be20fe25
Mercer, P.F.
6859877c-f46f-4f00-a0a8-56859973d842
Shute, J.K.
21aa47b2-7a14-4706-981d-f6cc6be58bf4
Bhowmik, A.
f7bc595d-eb75-48ab-b4d7-98a4fb47a258
Donaldson, G.C.
918ca6d7-df9d-4c9b-add7-8de7f9f5ab70
Wedizicha, J.A.
8d5f0942-8d89-4e9e-8718-6fe39a936543
Warner, J.A.
8571b049-31bb-4a2a-a3c7-4184be20fe25

Mercer, P.F., Shute, J.K., Bhowmik, A., Donaldson, G.C., Wedizicha, J.A. and Warner, J.A. (2005) MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respiratory Research, 6 (1), 151-[9pp]. (doi:10.1186/1465-9921-6-151).

Record type: Article

Abstract

BACKGROUND: Irreversible airflow obstruction in Chronic Obstructive Pulmonary Disease (COPD) is thought to result from airway remodelling associated with aberrant inflammation. Patients who experience frequent episodes of acute deterioration in symptoms and lung function, termed exacerbations, experience a faster decline in their lung function, and thus over time greater disease severity. However the mechanisms by which these episodes may contribute to decreased lung function are poorly understood. This study has prospectively examined changes in sputum levels of inflammatory cells, MMP-9 and TIMP-1 during exacerbations comparing with paired samples taken prior to exacerbation. METHODS: Nineteen COPD patients ((median, [IQR]) age 69 [63 to 74], forced expiratory volume in one second (FEV1) 1.0 [0.9 to 1.2], FEV1% predicted 37.6 [27.3 to 46.2]) provided sputa at exacerbation. Of these, 12 were paired with a samples collected when the patient was stable, a median 4 months [2 to 8 months] beforehand. RESULTS: MMP-9 levels increased from 10.5 microg/g [1.2 to 21.1] prior to exacerbation to 17.1 microg/g [9.3 to 48.7] during exacerbation (P < 0.01). TIMP-1 levels decreased from 3.5 microg/g [0.6 to 7.8] to 1.5 microg/g [0.3 to 4.9] (P = 0.16). MMP-9/TIMP-1 Molar ratio significantly increased from 0.6 [0.2 to 1.1] to 3.6 [2.0 to 25.3] (P < 0.05). Neutrophil, eosinophil and lymphocyte counts all showed significant increase during exacerbation compared to before (P < 0.05). Macrophage numbers remained level. MMP-9 levels during exacerbation showed highly significant correlation with both neutrophil and lymphocyte counts (Rho = 0.7, P < 0.01). CONCLUSION: During exacerbation, increased inflammatory burden coincides with an imbalance of the proteinase MMP-9 and its cognate inhibitor TIMP-1. This may suggest a pathway connecting frequent exacerbations with lung function decline.

This record has no associated files available for download.

More information

Published date: December 2005

Identifiers

Local EPrints ID: 45453
URI: http://eprints.soton.ac.uk/id/eprint/45453
ISSN: 1465-9921
PURE UUID: 1fb68bf0-ccb2-40bd-8978-6490d06ce298

Catalogue record

Date deposited: 29 Mar 2007
Last modified: 15 Mar 2024 09:11

Export record

Altmetrics

Contributors

Author: P.F. Mercer
Author: J.K. Shute
Author: A. Bhowmik
Author: G.C. Donaldson
Author: J.A. Wedizicha
Author: J.A. Warner

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×